Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Date:11/9/2012

CRANBURY, N.J., Nov. 9, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2013 financial results on Wednesday, November 14, 2012 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2012, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast

  • Q1 Fiscal Year 2013 Financial Results Press Release
  • 11/14/2012 at 7:30 a.m. ET

     

  • Q1 Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012 at 11:00 a.m. ET
    1-888-428-9490
    1-719-325-2354

    9649528

     

  • Q1 Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 11/14/2012-11/20/2012
    1-888-203-1112
    1-719-457-0820
    9649528

     

  • Webcast Live and Replay Access
  • http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.com. About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
    3. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    4. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    5. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    6. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    7. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/8/2016)... ... December 08, 2016 , ... ... control cells — optogenetics — is key to exciting advances in the study ... spatially patterned light projected via free-space optics stimulates small, transparent organisms and excites ...
    (Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
    (Date:12/8/2016)... Iowa (PRWEB) , ... December 08, 2016 , ... This ... asynchronous approvals for biotech crops. The authors focus on the economic effects in countries ... global approval of new biotech crops and the resultant risk of low level presence ...
    (Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
    Breaking Biology Technology:
    (Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
    (Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
    (Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
    Breaking Biology News(10 mins):